Information
Cyclophosphamide + Doxorubicin + 5-Flourouracil (CAF)1,43- Prechemo: CBC, Chem, LFTs, and CA 27-29. MUGA scan. 5-HT3 and dexamethasone 20 mg. Moderately to highly emetogenic.
- Cyclophosphamide 600 mg/m2: IV in 500–1000 cc NS IV on day 1.
- Doxorubicin 60 mg/m2: IV push on day 1. Potent vesicant.
- 5-Flourouracil 600 mg/m2: IV push on day 1.
- Side effects: Cyclophosphamide can cause rhinitis and irritation of nose and throat. Myelosuppression dose-limiting. G-CSF recommended. Nausea and vomiting, acute or delayed. Stomatitis and diarrhea can be severe and dose-limiting. Acutely, pericarditis-myocarditis syndrome may occur. With cumulative doses >550 mg/m2 doxorubicin, cardiomyopathy may occur. Cyclophosphamide may increase the risk of doxorubicin-induced cardiotoxicity. Dose reduce with liver dysfunction. Hemorrhagic cystitis, dysuria, and urinary frequency with cyclophosphamide. Red-orange discoloration of urine. SIADH. Hyperpigmentation, photosensitivity, nail changes, and radiation recall occur. Complete alopecia. Hand-foot syndrome can be dose-limiting. Photophobia, increased lacrimation, acute and chronic conjunctivitis, blepharitis, and blurred vision.
- Chair time: 2 hours on day 1. Repeat cycle every 21 days for six cycles.